Drug Trial Radar · NCT07826195
A Phase IIa Study Evaluating Injectable ALK-N001 in Patients With Advanced Gastrointestinal Tumors
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
174
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Dec 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- Zhejiang Anglikang Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, multicenter Phase IIa study is to evaluate the efficacy and safety of injectable ALK-N001 in patients with advanced gastrointestinal tumors, with the primary objective to assess its preliminary efficacy.
Conditions
- Advanced Gastrointestinal Tumors
Interventions
Injectable ALK-N001Drug
Injectable ALK-N001 is administered intravenously every 2 weeks (Q2W; 28-day treatment cycle). Two predefined dose levels are available: 37.5 mg/m² (Dose A) and 50 mg/m² (Dose B). Enrollment or suspension of dose groups may be determined by the Safety Review Committee (SRC) based on safety, PK, PD and preliminary anti-tumor activity data.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR), assessed per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Up to approximately 24 months from the first dose.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.